Immunosuppression News and Research

RSS
Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.
Mayo Clinic initiates enrollment in first U.S. clinical Hand Transplant Program

Mayo Clinic initiates enrollment in first U.S. clinical Hand Transplant Program

Athersys presents MultiStem phase I study results at TCT Conference

Athersys presents MultiStem phase I study results at TCT Conference

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

FDA grants orphan drug designation for MultiStem stem cell therapy

FDA grants orphan drug designation for MultiStem stem cell therapy

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

Removing corticosteroid regimen after surgery results in better graft survival rates

Removing corticosteroid regimen after surgery results in better graft survival rates

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

New T cell engineering approach can improve success rate of immune-cell therapies

New T cell engineering approach can improve success rate of immune-cell therapies

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

NKTreg white blood cells migrate into liver, suppress immune responses: Research

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Immunosuppressive properties of TNF blockers may increase risk of malignancy in children

Immunosuppressive properties of TNF blockers may increase risk of malignancy in children

TNF blockers may increase the risk of malignancy in children

TNF blockers may increase the risk of malignancy in children

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

New guidelines for care of heart transplant recipients from ISHLT

New guidelines for care of heart transplant recipients from ISHLT

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.